Direct oral anticoagulants: A user's guide

Suvash Shrestha; On Chen; Robert Frankel; Yisachar Greenberg; Felix Yang

Direct oral anticoagulants: A user's guide

Suvash Shrestha
, On Chen
, Robert Frankel
, Yisachar Greenberg
, Felix Yang

Department of Medicine - Division of Cardiology

Rhode Island Hospital
Maimonides Medical Center

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Direct oral anticoagulants (DOACs)-dabigatran, rivaroxaban, apixaban, and edoxaban-are available alternatives to warfarin for oral anticoagulation. Studies have proven the efficacy of DOACs in stroke prevention in nonvalvular atrial fibrillation, in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and as prophylaxis against DVT and PE in patients undergoing hip or knee replacement surgery. DOACs have fewer drug interactions than warfarin. Among DOACs, apixaban has a notably low rate of gastrointestinal tract bleeding, whereas dabigatran has demonstrated a significant reduction in the rate of ischemic stroke. This article reviews the data and practices regarding the use of DOACs.

Original language	English
Journal	Consultant
Volume	57
Issue number	4
State	Published - Apr 2017

Keywords

Apixaban
Atrial fibrillation
Dabigatran
Deep vein thrombosis
Direct oral anticoagulants
Edoxaban
Pulmonary embolism
Rivaroxaban
Stroke prevention
Warfarin

Cite this

@article{ca6b343bacb643f5b3ddc97aa79cee30,

title = "Direct oral anticoagulants: A user's guide",

abstract = "Direct oral anticoagulants (DOACs)-dabigatran, rivaroxaban, apixaban, and edoxaban-are available alternatives to warfarin for oral anticoagulation. Studies have proven the efficacy of DOACs in stroke prevention in nonvalvular atrial fibrillation, in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and as prophylaxis against DVT and PE in patients undergoing hip or knee replacement surgery. DOACs have fewer drug interactions than warfarin. Among DOACs, apixaban has a notably low rate of gastrointestinal tract bleeding, whereas dabigatran has demonstrated a significant reduction in the rate of ischemic stroke. This article reviews the data and practices regarding the use of DOACs.",

keywords = "Apixaban, Atrial fibrillation, Dabigatran, Deep vein thrombosis, Direct oral anticoagulants, Edoxaban, Pulmonary embolism, Rivaroxaban, Stroke prevention, Warfarin",

author = "Suvash Shrestha and On Chen and Robert Frankel and Yisachar Greenberg and Felix Yang",

year = "2017",

month = apr,

language = "English",

volume = "57",

journal = "Consultant",

issn = "0010-7069",

number = "4",

}

TY - JOUR

T1 - Direct oral anticoagulants

T2 - A user's guide

AU - Shrestha, Suvash

AU - Chen, On

AU - Frankel, Robert

AU - Greenberg, Yisachar

AU - Yang, Felix

PY - 2017/4

Y1 - 2017/4

N2 - Direct oral anticoagulants (DOACs)-dabigatran, rivaroxaban, apixaban, and edoxaban-are available alternatives to warfarin for oral anticoagulation. Studies have proven the efficacy of DOACs in stroke prevention in nonvalvular atrial fibrillation, in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and as prophylaxis against DVT and PE in patients undergoing hip or knee replacement surgery. DOACs have fewer drug interactions than warfarin. Among DOACs, apixaban has a notably low rate of gastrointestinal tract bleeding, whereas dabigatran has demonstrated a significant reduction in the rate of ischemic stroke. This article reviews the data and practices regarding the use of DOACs.

AB - Direct oral anticoagulants (DOACs)-dabigatran, rivaroxaban, apixaban, and edoxaban-are available alternatives to warfarin for oral anticoagulation. Studies have proven the efficacy of DOACs in stroke prevention in nonvalvular atrial fibrillation, in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and as prophylaxis against DVT and PE in patients undergoing hip or knee replacement surgery. DOACs have fewer drug interactions than warfarin. Among DOACs, apixaban has a notably low rate of gastrointestinal tract bleeding, whereas dabigatran has demonstrated a significant reduction in the rate of ischemic stroke. This article reviews the data and practices regarding the use of DOACs.

KW - Apixaban

KW - Atrial fibrillation

KW - Dabigatran

KW - Deep vein thrombosis

KW - Direct oral anticoagulants

KW - Edoxaban

KW - Pulmonary embolism

KW - Rivaroxaban

KW - Stroke prevention

KW - Warfarin

UR - https://www.scopus.com/pages/publications/85026803081

M3 - Article

AN - SCOPUS:85026803081

SN - 0010-7069

VL - 57

JO - Consultant

JF - Consultant

IS - 4

ER -

Direct oral anticoagulants: A user's guide

Abstract

Keywords

Other files and links

Fingerprint

Cite this